The AP1S1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of HAP1 cells, engineered for loss-of-function investigation of the AP1S1 gene. This product comprises a heterogeneous pool of cells carrying targeted disruptions in AP1S1, introduced via CRISPR/Cas9-mediated gene editing, providing a versatile tool to dissect adaptor protein 1 (AP-1) complex functions. As a polyclonal knockout model, it reflects diverse editing outcomes across the population while maintaining the benefits of the HAP1 near-haploid background. The product is designed for researchers studying clathrin-dependent trafficking, lysosomal protein sorting, and related disease mechanisms without the need for clonal isolation.
HAP1 cells are a near-haploid human male cell line derived from the chronic myeloid leukemia cell line KBM-7. Their haploid genome simplifies genetic manipulation and phenotypic analysis, making HAP1 a preferred system for high-throughput functional genomics and drug screening. Despite their leukemic origin, HAP1 cells retain intact intracellular trafficking pathways, including clathrin-mediated endocytosis and Golgi-to-endosome transport. This genetic simplicity, combined with authentic expression of trafficking machinery, renders HAP1 an ideal host for knockout models aimed at dissecting membrane traffic, receptor dynamics, and protein sorting.
AP1S1 encodes the sigma-1 subunit of the heterotetrameric AP-1 adaptor complex, a master regulator of clathrin-coated vesicle formation at the trans-Golgi network (TGN) and endosomes. The core AP-1 complex consists of AP1G1, AP1B1, AP1M1, and AP1S1, and is activated by the ARF1 GTPase and phosphatidylinositol-4-phosphate on donor membranes. AP1S1 directly contributes to cargo recognition by binding tyrosine-based and dileucine-based sorting motifs on transmembrane clients. Critical downstream targets include the mannose-6-phosphate receptor (M6PR), which routes lysosomal hydrolases, and MHC class I molecules. AP1S1-knockout disrupts this sorting machinery, leading to mislocalization of lysosomal enzymes and surface receptors. The complex interacts with clathrin, epsinR, and other accessory factors to ensure accurate vesicle biogenesis. Mutations in AP1S1 cause MEDNIK syndrome, a severe neurocutaneous disorder, highlighting its indispensable role in intracellular transport.
Ablation of AP1S1 in HAP1 cells creates a powerful model to study AP-1-dependent trafficking defects. The polyclonal knockout population enables examination of heterogeneous functional consequences, from lysosomal enzyme secretion to altered surface receptor expression. This system supports detailed mechanistic studies using a variety of assays, including immunofluorescence microscopy to monitor TGN/endosome markers, transferrin receptor internalization assays, and flow cytometric quantification of MHC class I levels. Co-immunoprecipitation can probe residual AP-1 complex assembly. By recapitulating core features of MEDNIK syndrome and related congenital disorders of glycosylation, this model is well-suited for exploring therapeutic interventions and chemical modulators of trafficking.
This knockout product is intended for diverse research applications, including high-content screening for small molecules that restore lysosomal enzyme delivery, CRISPR-based synthetic lethality screens, and functional dissection of endosomal sorting pathways. It is particularly valuable for investigating lysosomal storage disorders, neurocutaneous syndromes, and protein mislocalization diseases. The cells are provided as a live polyclonal population ready for expansion and immediate use in cellular trafficking experiments. For further details, please contact Ascent Research.
